Rocket Lab keeps executing, guiding Q3 revenue to $250-265M, up 61-70% year over year and above the roughly $236M analyst estimate. Q2 results were mostly in line with expectations, with revenue up 62% year over year. x.com 

Rocket Lab's latest quarter supports a move toward $122, with growth, backlog and guidance all stepping up. Revenue cleared about $200M, up roughly 60% year over year, and backlog now exceeds $2B. Liquidity is strong, with about $1.5B in cash and more than $2B in total liquidity. Management again guided Q2 higher, to $232M versus a $208M street consensus. x.com 

Rocket Lab shares look set to grind as Neutron's first flight slips, even though the core business is at its strongest. Q2 revenue hit a record $234.1M, up 62%, and backlog rose 137% to $2.356B. But the Q3 guide cuts GAAP gross margin to 29-31% from 36.1%, below the ~37.6% expected, with adjusted EBITDA losses widening to $17-23M on low-margin satellite programs, Mynaric integration and Neutron spending. A Q1 2027 Neutron debut is now the base case, which will disappoint high expectations. x.com 

Rocket Lab delivered a really bullish report. Per @allday_stocks, Q1 revenue of $200.3M beat the $189.41M estimate, up 63.5% year on year, with a record 38.2% GAAP gross margin and backlog up 20.2% quarter on quarter to $2.2B. It sold more launches in Q1 than in all of 2025, guided Q2 revenue to $225-240M versus $205.18M expected, and Neutron remains on track to debut later this year, with defense momentum tied to Golden Dome and hypersonics. x.com 

Rocket Lab's bounce has room to run to $65 after buyers returned following shipment of Neutron's second stage to its Virginia launch site. A break above $65 before November 9 results remains the real test. x.com 

Rocket Lab still looks ridiculously expensive at 29 times forward sales against SpaceX at 22 times, even after a 65% fall. At 22 times, Rocket Lab would be roughly $38, and SpaceX would still be the pick. SpaceX also has better forward guidance; Rocket Lab's negative adjusted EBITDA makes sales multiples the valuation yardstick. x.com  x.com  x.com  x.com 

Rocket Lab's growing Space Systems business positions it to provide more than launches for the space economy. It generated $189.5M in Q2, 81% of revenue; if its pending Iridium acquisition closes, it would gain a global satellite communications network. At about $51, this is one of the most compelling long-term opportunities in the space sector over 3-5 years, provided it keeps executing. Neutron's launch has slipped to 2027, and execution risks remain. x.com  x.com  x.com 

Good SpaceX earnings could help Rocket Lab lead the new-space sector higher with a rally as violent as its capitulation. Rocket Lab is the sector leader outside SpaceX; its RSI is extremely oversold, the lower Bollinger band is overstretched and MACD's negative divergence is subsiding. Three upside gaps lie at $55.25-59.18, $64.22-65.71 and $73.11-74.76. The highest should fill before year-end, though the exact date is hard to predict. x.com  x.com 

Repeated Neutron delays undermine the premium on Rocket Lab stock when execution keeps slipping. The company does not live or die by Neutron, but 50x sales was unjustified; even at 26x 2027 sales, a legitimate price suggests another 50% decline. x.com  x.com 

Rocket Lab's defense contracts and backlog position it to benefit from national-security spending. Its $2.36B backlog includes over 100 booked launches, with an $816M SDA satellite deal and a $266M Space Force HASTE deal for hypersonic testing. Despite the Neutron delay, its $36B valuation offers one of the space sector's best risk-reward setups: exposure to the same defense and space-infrastructure trend as SpaceX at a fraction of its valuation. Rocket Lab is headed above $100. x.com